Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6945770 | 0.82 | CES2 (0.52) | CES2CES1L3MBTL1ACKR3ALDH1A1 | |
| SCHEMBL30115025 | 0.82 | CES2 (0.52) | CES2CES1L3MBTL1ACKR3ALDH1A1 | |
| SCHEMBL20628934 | 0.81 | CES2 (0.47) | CES2CES1L3MBTL1ACKR3ALDH1A1 | |
| SCHEMBL20179628 | 0.81 | HPGD (0.41) | ALDH1A1PKM | |
| SCHEMBL20156497 | 0.81 | TRPA1 (0.39) | — | |
| SCHEMBL12181058 | 0.80 | CES2 (0.50) | CES2CES1L3MBTL1ACKR3ALDH1A1 | |
| SCHEMBL19881417 | 0.80 | CES2 (0.50) | CES2CES1L3MBTL1ACKR3ALDH1A1 | |
| SCHEMBL28762823 | 0.80 | CES2 (0.50) | CES2CES1L3MBTL1ACKR3ALDH1A1 | |
| SCHEMBL30601057 | 0.80 | CES2 (0.50) | CES2CES1L3MBTL1ACKR3ALDH1A1 | |
| SCHEMBL16560497 | 0.79 | CES2 (0.58) | CES2CES1L3MBTL1ALDH1A1CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023130043-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT OF ANXIETY | PSY THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2020249096-A1 | FUSED RING COMPOUND AS FGFR AND VEGFR DUAL INHIBITOR | 南京明德新药研发有限公司 | 2020-12-17 | — | — | WO | disclosed |
| WO-2018132288-A1 | AZIRIDINE SPINOSYN DERIVATIVES AND METHODS OF MAKING | AGRIMETIS, LLC (US) | 2018-07-19 | — | — | WO | disclosed |
| US-9206146-B2 | Purification of posaconazole and of posaconazole intermediates | SANDOZ AG (CH) | 2015-12-08 | — | — | US | disclosed |
| US-9073904-B2 | Preparation of posaconazole intermediates | SANDOZ AG (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073904-B2 | Preparation of posaconazole intermediates | SANDOZ AG (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20130211086-A1 | PURIFICATION OF POSACONAZOLE AND OF POSACONAZOLE INTERMEDIATES | SANDOZ AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-20130203994-A1 | PREPARATION OF POSACONAZOLE INTERMEDIATES | SANDOZ AG (CH) | 2013-08-08 | — | — | US | disclosed |
| US-20130203994-A1 | PREPARATION OF POSACONAZOLE INTERMEDIATES | SANDOZ AG (CH) | 2013-08-08 | — | — | US | disclosed |
| CN-102369198-A | Triazole antifungal agents | NIAN WU | 2012-03-07 | — | — | CN | disclosed |
| WO-2011035518-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | 辽宁利锋科技开发有限公司 (CN) | 2011-03-31 | — | — | WO | disclosed |
| US-20100143455-A1 | Triazole antifungal agents | WU NIAN | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203994-A1 | PREPARATION OF POSACONAZOLE INTERMEDIATES | ERG28, CYP51A1, CYP2F1 | CES2 2615/4885CES1 1127/4885L3MBTL1 4639/4885 |
| US-20100143455-A1 | Triazole antifungal agents | CYP3A7, ERG28, UGT1A7 | CES2 1657/4885CES1 1730/4885L3MBTL1 1247/4885 |
| US-20130211086-A1 | PURIFICATION OF POSACONAZOLE AND OF POSACONAZOLE INTERMEDIATES | CYP2F1, ERG28, F12 | CES2 2441/4885CES1 718/4885L3MBTL1 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.